EC Number |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
---|
1.1.1.224 | Acquired Immunodeficiency Syndrome |
32079455 |
Trehalose limits opportunistic mycobacterial survival during HIV co-infection by reversing HIV-mediated autophagy block. |
ongoing research unassigned |
2 0 |
1.1.1.224 | Amyotrophic Lateral Sclerosis |
33632058 |
C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. |
causal interaction unassigned |
1 0 |
1.1.1.224 | Fabry Disease |
22768187 |
Mannose 6-phosphate receptor and sortilin mediated endocytosis of ?-galactosidase A in kidney endothelial cells. |
causal interaction unassigned |
3 0 |
1.1.1.224 | Frontotemporal Dementia |
33632058 |
C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. |
causal interaction unassigned |
1 0 |
1.1.1.224 | Infections |
29277005 |
Landmarks of endosomal remodeling in the early phase of cytomegalovirus infection. |
therapeutic application unassigned |
1 0 |
1.1.1.224 | Infections |
32493818 |
Exocytosis of Progeny Infectious Varicella-Zoster Virus Particles via a Mannose-6-Phosphate Receptor Pathway without Xenophagy following Secondary Envelopment. |
unassigned |
0 |
1.1.1.224 | Melanoma |
30765391 |
BRAF targeting sensitizes resistant melanoma to cytotoxic T cells. |
causal interaction ongoing research therapeutic application unassigned |
3 1 4 0 |
1.1.1.224 | Mucolipidoses |
18559255 |
Sortilin mediates the lysosomal targeting of cathepsins D and H. |
unassigned |
0 |
1.1.1.224 | Neoplasms |
17507477 |
Insulin-like growth factor II receptor-mediated intracellular retention of cathepsin B is essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus. |
causal interaction ongoing research unassigned |
3 4 0 |
1.1.1.224 | Neoplasms |
30621390 |
Tumor Microenvironmental pH and Enzyme Dual Responsive Polymer-Liposomes for Synergistic Treatment of Cancer Immuno-Chemotherapy. |
causal interaction ongoing research therapeutic application unassigned |
3 3 4 0 |